Alkem Laboratories Launches NeuCeno Epilepsy Drug in India
Alkem Laboratories has launched NeuCeno (cenobamate), a new anti-seizure medication for adults with partial-onset seizures, marking its first introduction in India. NeuCeno is a once-daily oral therapy available in multiple strengths and works through a dual mechanism targeting neuronal activity. Epilepsy affects an estimated 9.4 million people in India, with many experiencing uncontrolled seizures despite existing treatments. Clinical studies showed cenobamate reduced seizure frequency by up to 78%, with some patients achieving seizure freedom during maintenance.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 37/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 16 Sept, 07:41 am. Other outlets followed.
- 1businessstandard16 Sept, 07:41 amAlkem Labs launches epilepsy management drug Cenobamate in India
- 2businessstandard16 Sept, 12:35 pmAlkem launches anti-seizure medication - NeuCeno in India
Who's involved
Institutions and figures named across source coverage.
Story context
- Category
- Business
- Location
- India
- Sources analysed
- 2
- Last analysed
- 16 Sept 2026
- Key entities
- SeizureCenobamateAnticonvulsantEpilepsyIndiaQuality of lifeHealth careFocal seizureGABAA receptorMechanism of actionAction potentialSodium